The role of EGFR Tyrosine Kinase inhibitors in fist line NSCLC treatment

Dec 15, 2013

390 likes | 858 Views

Share Presentation

Embed Code

Link

lazzaro

Download Presentation

The role of EGFR Tyrosine Kinase inhibitors in fist line NSCLC treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

anticancer agentsprotein kinase inhibitors

Protein Kinases. Enzymes that catalyse phosphorylation reactions on protein substrates500-2000 estimated protein kinases in a cellProtein kinases are present in the cytoplasmProtein kinase receptors - dual role as receptor and enzymeOverexpression can result in cancerTyrosine kinases, serine-threonine kinases and histidine kinasesATP used as enzyme cofactor - phosphorylating agent.

855 views • 48 slides

EGFR Inhibitors in Advanced NSCLC

Lung Cancer - Background. Leading cause of cancer-related mortality 2007 statistics: 210k new cases 160k deaths~87%: non-small cell lung cancer (NSCLC)*Median survival ~10 mos. (advanced stage). *Govindan R, Page N, Morgensztern D et al., J Clin Oncol 2006; 24:4539-44.. Lung Cancer - Epidemiolo

836 views • 29 slides

Anticancer Therapy: Kinase Inhibitors

Anticancer Therapy: Kinase Inhibitors. Charles Harrell. Outline of Material Presented. Definition of Cancer Understanding Kinases Kinase Inhibitor Functionality Economic Considerations Assigned Reading Homework Questions. What is Cancer?.

477 views • 20 slides

EGFR gene mutation testing in NSCLC

EGFR gene mutation testing in NSCLC. Rachel Butler All Wales Molecular Genetics Laboratory. Benefits of stratified medicine. Reduce adverse reactions Reduce morbidity and patient distress Reduce associated costs Improve patient response through correct dose or effective therapy

785 views • 31 slides

MEK Inhibitors and their potential role in relapsed NSCLC

MEK Inhibitors and their potential role in relapsed NSCLC. Ranee Mehra, MD Fox Chase Cancer Center Philadelphia, PA. Disclosures. Consulting – Novartis, Bristol Myers Squib Spouse is employee of GSK Acknowledgment: J. Weiss. Ras-Raf-MEK-ERK1/2 MAP kinase pathway.

623 views • 30 slides

Primer on Kinase Inhibitors

Primer on Kinase Inhibitors. Richard R. Furman Directory, CLL Research Center Weill Cornell Medical College / New York Presbyterian Hospital. BCR-associated Kinases: Proven Effective Therapeutic Targets. Syk (spleen tyrosine kinase): R406, PRT062070.

831 views • 34 slides

Inhibition of Cancer cells by Iressa, an EGFR Tyrosine Kinase Inhibitor

Inhibition of Cancer cells by Iressa, an EGFR Tyrosine Kinase Inhibitor. Presenters Naser Shams and Jim McCarthy. Terms to Know. Epithelial - skin and other lining tissues Endothelial - epithelial tissue lining blood vessels Angiogenesis - creation of blood vessels

450 views • 23 slides

Discontinuation of second generation tyrosine kinase inhibitors

Discontinuation of second generation tyrosine kinase inhibitors. Dr Delphine Rea Service des Maladies du Sang Hôpital Saint-Louis Paris, France Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques). CML and MPDs UK national meeting Newcastle, March 1 st , 2013.

494 views • 17 slides

Global Epidemiologic Variability of EGFR Mutation NSCLC

Global Epidemiologic Variability of EGFR Mutation NSCLC. Keunchil Park, MD, PhD Professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center Seoul, Korea.

406 views • 8 slides

Tyrosine Kinase Inhibitors in non-small cell lung cancer

Giuseppe Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliated Branches. Tyrosine Kinase Inhibitors in non-small cell lung cancer. Estimated Cancer Death Rates in the United States 2009 Men 292,540; Women 269,800. Lung and bronchus 30% Prostate 9% Colon and rectum 9% Pancreas 6%

1.97k views • 97 slides

Therapeutic Drug Monitoring (TDM) of Tyrosine Kinase Inhibitors (TKI) in MRCC

Therapeutic Drug Monitoring (TDM) of Tyrosine Kinase Inhibitors (TKI) in MRCC. Réunion GSO Uro 19 Février 2014. TDM “Therapeutic Drug Monitoring”. Determination of plasma concentrations as a “routine” practice in order to adapt the individual dose Prerequisite of TDM :

706 views • 30 slides

Tyrosine Kinase inhibitors

Tyrosine Kinase inhibitors. Presented BY : Group 5, PharmD . Supervised by : Dr. Nashaat. Imatinib resistance. Resistance to imatinib is still a problem ,mainly in patients in the accelerated Or blast crisis phases of the disease.

1.53k views • 12 slides

First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC. Jürgen Wolf, MD Medical Director, Center for Integrated Oncology Köln Department I of Internal Medicine University Hospital of Cologne Bonn, Germany. Pivotal Registration Trials With EGFR TKIs in EGFR Mutation-Positive NSCLC.

400 views • 8 slides

Update on the Side Effects of Tyrosine Kinase Inhibitors

Update on the Side Effects of Tyrosine Kinase Inhibitors. Dr Jenny Byrne Nottingham University Hospitals Trust. IRIS Study: Most Frequently Reported AEs. Imatinib is a Safe Drug. Only Serious Adverse Events (SAEs) were collected after 2005

988 views • 28 slides

FDA Evaluation of Hepatotoxicity Related to Tyrosine Kinase Inhibitors

FDA Evaluation of Hepatotoxicity Related to Tyrosine Kinase Inhibitors. J Chang, 1 M Rand, 2 G Blumenthal, 1 P Cortazar, 1 C Kulick, 2 E Hausman, 2 S Chang, 2 R Pratt, 2 B Habtemariam, 3 Y Chen, 3 J Bullock, 3 RC Orbach, 3 I Zineh, 3 R Justice, 1 R Pazdur 4.

345 views • 14 slides

Tyrosine Protein Kinase ABL1

Tyrosine Protein Kinase ABL1. Mira Patel H Molecular Human Anatomy. Kinases. Attach a phosphate group to an amino acid residue of a protein Result is usually a conformational change that activates the substrate protein Activation allows proteins to take part in chemical reactions

541 views • 27 slides

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK)

The report provides comprehensive information on the Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

183 views • 5 slides

Tyrosine Protein Kinase Mer (Receptor Tyrosine Kinase MerTK)-Pipeline Review, H1 2017-Industry Report

The report provides in depth analysis on Tyrosine Protein Kinase Mer targeted pipeline therapeutics.

76 views • 3 slides

neurotrophic tyrosine kinase, receptor, type 1

This gene encodes a member of the neurotrophic tyrosine kinase receptor (NTKR) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway.

90 views • 6 slides

Second and Third Generation Tyrosine Kinase Inhibitors: How do we Choose?

Second and Third Generation Tyrosine Kinase Inhibitors: How do we Choose?. Dr Jenny Byrne Nottingham. Imatinib is a wonderful drug !. 1. 0. 0. 9. 0. 8. 0. 7. 0. i. Es. t. imaa. t. e. d. o. v. e. r. a. l. l. s. u. r. ivaa. i. l. m. l. 6. 0. a. t. 8. y. e.

383 views • 36 slides

Tyrosine Kinase Inhibitors PHL 425

Tyrosine Kinase Inhibitors PHL 425. Dr. Mohamed M. Sayed-AShmed. Tyrosine Kinases. There are 2 major classes of tyrosine kinases.

227 views • 16 slides

1-line Treatment of Advanced-NSCLC WT

1-line Treatment of Advanced-NSCLC WT. Cesare Gridelli Division of Medical Oncology “S.G. Moscati” Hospital – Avellino (Italy) cgridelli@libero.it. First-Line Treatment of A-NSCLC in EU. EGFR mutation (del 19 or L858R in exon 21). EGFR-TKI. Radiotherapy CNS Central airways Bone

298 views • 28 slides

More Related